Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in NeoGenomics, Inc., Surgery Partners or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how NeoGenomics, Inc., Surgery Partners and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About NeoGenomics, Inc., Surgery Partners and Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Latest Health Care Providers & Services and NeoGenomics, Inc., Surgery Partners, Inc. Stock News

As of July 31, 2026, NeoGenomics, Inc. had a $2.0 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. NeoGenomics, Inc.’s stock is up 30% in 2026, up 10.1% in the previous five trading days and up 199.8% in the past year.

Currently, NeoGenomics, Inc. does not have a price-earnings ratio. NeoGenomics, Inc.’s trailing 12-month revenue is $766.3 million with a -6.8% net profit margin. Year-over-year quarterly sales growth most recently was 11.3%. Analysts expect adjusted earnings to reach $0.183 per share for the current fiscal year. NeoGenomics, Inc. does not currently pay a dividend.

As of July 31, 2026, Surgery Partners, Inc. had a $2.0 billion market cap, putting it in the 54th percentile of all stocks. Surgery Partners, Inc.’s stock is down 0.3% in 2026, down 2.1% in the previous five trading days and down 31.16% in the past year.

Currently, Surgery Partners, Inc. does not have a price-earnings ratio. Surgery Partners, Inc.’s trailing 12-month revenue is $3.3 billion with a -2.3% net profit margin. Year-over-year quarterly sales growth most recently was 4.5%. Analysts expect adjusted earnings to reach $0.465 per share for the current fiscal year. Surgery Partners, Inc. does not currently pay a dividend.

How We Compare NeoGenomics, Inc., Surgery Partners and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at NeoGenomics, Inc., Surgery Partners and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

NeoGenomics, Inc., Surgery Partners and Inc. Growth Grades

Company	Ticker	Growth
NeoGenomics, Inc.	NEO	C
Surgery Partners, Inc.	SGRY	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

NeoGenomics, Inc. has a Growth Score of 49, which is Average. Surgery Partners, Inc. has a Growth Score of 89, which is Very Strong.

The Growth Grade Winner: Surgery Partners, Inc.

As you can clearly see from the Growth Grade breakdown above, Surgery Partners, Inc. has a more attractive growth grade than NeoGenomics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Surgery Partners, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

NeoGenomics, Inc., Surgery Partners and Inc.’s Momentum Grades

Company	Ticker	Momentum
NeoGenomics, Inc.	NEO	A
Surgery Partners, Inc.	SGRY	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

NeoGenomics, Inc. has a Momentum Score of 98, which is Very Strong. Surgery Partners, Inc. has a Momentum Score of 29, which is Weak.

The Momentum Grade Winner: NeoGenomics, Inc.

As you can clearly see from the Momentum Grade breakdown above, NeoGenomics, Inc. is considered to have stronger momentum compared to Surgery Partners, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, NeoGenomics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

NeoGenomics, Inc., Surgery Partners and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
NeoGenomics, Inc.	NEO	C
Surgery Partners, Inc.	SGRY	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

NeoGenomics, Inc. has a Earnings Estimate Score of 41, which is Neutral. Surgery Partners, Inc. has a Earnings Estimate Score of 63, which is Positive.

The Earnings Estimate Revisions Grade Winner: Surgery Partners, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Surgery Partners, Inc. has a better Earnings Estimate Revisions Grade than NeoGenomics, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Surgery Partners, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other NeoGenomics, Inc., Surgery Partners and Inc. Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether NeoGenomics, Inc., Surgery Partners and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, NeoGenomics, Inc., Surgery Partners or Inc. Stock?

Overall, NeoGenomics, Inc. stock has a Growth Score of 49, Momentum Score of 98 and Estimate Revisions Score of 41.

Surgery Partners, Inc. stock has a Growth Score of 89, Momentum Score of 29 and Estimate Revisions Score of 63.

Comparing NeoGenomics, Inc., Surgery Partners and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.